Gilead Sciences Reports Overall Survival Data for Trodelvy in Triple-Negative Breast Cancer

Gilead Sciences today presented overall survival data from the Phase 3 ASCENT trial evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with previously treated metastatic triple-negative breast cancer (TNBC). The data showed a significant improvement in overall survival with Trodelvy compared to single-agent chemotherapy, with a median overall survival of 12.1 months versus 6.7 months.